XML 36 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Equity Method Accounting for Common Stock of Asterias, at fair value (Tables)
 9 Months Ended
Sep. 30, 2017
Asterias Biotherapeutics [Member]  
Schedule of Equity Method Investments [Line Items]  
Unaudited results of operations
The unaudited condensed results of operations for the three and nine months ended September 30, 2017 and 2016 and for the period from January 1, 2016 through May 12, 2016 are summarized below (in thousands):

  
Three Months Ended
September 30,
  
Nine Months Ended
September 30,
  
For the Period
January 1, 2016 to
May 12, 2016
 
  
2017
  
2016
  
2017
  
2016
    
Condensed Statements of Operations (unaudited) (1):
                 
Total revenue
 
$
1,688
  
$
2,076
  
$
4,014
  
$
5,202
  $
2,354
 
Gross profit
  
1,607
   
2,017
   
3,863
   
5,084
    2,301 
Loss from operations
  
(7,063
)
  
(7,425
)  
(24,703
) 
(25,591
)  (13,944
)
Net loss
 
$
(6,809
)
 
$
(10,648
) 
$
(21,824
)
$
(26,144
)$
(13,113
)

(1) The condensed unaudited statement of operations information included in the table above reflects Asterias' results of operations for the three and nine months ended September 30, 2017 and 2016. The periods shown are provided for comparative purposes only, and the condensed results of operations of Asterias shown for the three and nine months ended September 30, 2017 were not included in BioTime's condensed consolidated statements of operations. The unaudited results of operations of Asterias for the period January 1, 2016 through May 12, 2016 only are included in the unaudited condensed consolidated results of BioTime for the nine months ended September 30, 2016 due to the Asterias Deconsolidation on May 13, 2016.